Trials / Completed
CompletedNCT04346381
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
An Open-label, Multi-center，Phase II Study of Camrelizumab Combined With Famitinib in the Treatment of Advanced Solid Tumor
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 233 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of camrelizumab combined famitinib in subjects with selected advanced solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | Intravenous (IV) camrelizumab on Day 1 of each cycle |
| DRUG | Famitinib | famitinib po qd |
Timeline
- Start date
- 2020-06-05
- Primary completion
- 2022-06-22
- Completion
- 2022-06-22
- First posted
- 2020-04-15
- Last updated
- 2023-09-18
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04346381. Inclusion in this directory is not an endorsement.